- Home
- ASLE vs SNY Comparison
ASLE vs SNY Comparison
Compare ASLE & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASLE
- SNY
- Stock Information
- Founded
- ASLE 2008
- SNY 1994
- Country
- ASLE United States
- SNY France
- Employees
- ASLE N/A
- SNY N/A
- Industry
- ASLE Industrial Specialties
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- ASLE Consumer Discretionary
- SNY Health Care
- Exchange
- ASLE Nasdaq
- SNY Nasdaq
- Market Cap
- ASLE 322.4M
- SNY 123.6B
- IPO Year
- ASLE N/A
- SNY N/A
- Fundamental
- Price
- ASLE $6.09
- SNY $49.90
- Analyst Decision
- ASLE Strong Buy
- SNY Buy
- Analyst Count
- ASLE 3
- SNY 2
- Target Price
- ASLE $8.67
- SNY $62.50
- AVG Volume (30 Days)
- ASLE 462.3K
- SNY 3.1M
- Earning Date
- ASLE 05-07-2025
- SNY 04-24-2025
- Dividend Yield
- ASLE N/A
- SNY 3.21%
- EPS Growth
- ASLE N/A
- SNY 39.56
- EPS
- ASLE N/A
- SNY 5.45
- Revenue
- ASLE $320,302,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- ASLE $14.51
- SNY $5.35
- Revenue Next Year
- ASLE $18.41
- SNY $6.69
- P/E Ratio
- ASLE N/A
- SNY $18.73
- Revenue Growth
- ASLE N/A
- SNY N/A
- 52 Week Low
- ASLE $4.53
- SNY $45.80
- 52 Week High
- ASLE $9.40
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- ASLE 32.68
- SNY 37.47
- Support Level
- ASLE $5.75
- SNY $51.67
- Resistance Level
- ASLE $7.18
- SNY $55.73
- Average True Range (ATR)
- ASLE 0.28
- SNY 0.89
- MACD
- ASLE -0.03
- SNY -0.12
- Stochastic Oscillator
- ASLE 23.69
- SNY 0.34
About ASLE AerSale Corporation
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.